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Abstract
Background: Several classes of histone deacetylases (HDACs) are expressed in the spinal cord that is a critical
structure of the nociceptive pathway. HDAC-regulated histone acetylation is an important component of chromatin
remodeling leading to epigenetic regulation of gene transcription. To understand the role of histone acetylation in
epigenetic regulation of pathological pain, we have studied the impact of different classes of HDACs in the spinal
cord on inflammatory hyperalgesia induced by complete Freund’s adjuvant (CFA).
Results: We intrathecally applied inhibitors specific to different classes of HDACs and evaluated their impact on
inflammatory hyperalgesia. Pre-injected inhibitors targeting class I as well as II (SAHA, TSA, LAQ824) or IIa (VPA,
4-PB) HDACs significantly delayed the thermal hyperalgesia induced by unilateral CFA injection in the hindpaw.
Existing hyperalgesia induced by CFA was also attenuated by the HDAC inhibitors (HDACIs). In contrast, these
inhibitors did not interfere with the thermal response either in naïve animals, or on the contralateral side of
inflamed animals. Interestingly, MS-275 that specifically inhibits class I HDACs failed to alter the hyperalgesia
although it increased histone 3 acetylation in the spinal cord as SAHA did. Using immunoblot analysis, we further
found that the levels of class IIa HDAC members (HDAC4, 5, 7, 9) in the spinal dorsal horn were upregulated
following CFA injection while those of class I HDAC members (HDAC1, 2, 3) remained stable or were slightly
reduced.
Conclusions: Our data suggest that activity of class II HDACs in the spinal cord is critical to the induction and
maintenance of inflammatory hyperalgesia induced by CFA, while activity of class I HDACs may be unnecessary.
Comparison of the effects of HDACIs specific to class II and IIa as well as the expression pattern of different HDACs
in the spinal cord in response to CFA suggests that the members of class IIa HDACs may be potential targets for
attenuating persistent inflammatory pain.
Background
Gene expression in the nociceptive pathway plays an
important role in the induction and maintenance of per-
sistent pain, including inflammatory pain resulting from
tissue damage [1-3]. It has been found that dynamic
changes in the steady-state levels of mRNAs and/or pro-
teins in the peripheral and central nervous system occur
during the development of pathological pain and that
animals with specific gene knockout or knockdown
exhibit altered nociceptive responses and different sensi-
tivity to the development of pathological pain [1,4].
However, the molecular mechanisms underlying the
changes of mRNA and protein levels in pathological
pain conditions mostly remain unexplored except that
the status of a few transcription factors, e.g., deletion of
DREAM [5] and modifications of CREB [6] and NF-B
[7], were studied as single transcription factors and as a
result of activated signal pathways, and mutations in a
few genes have been found to be associated with the
alteration of pain sensitivity in humans [8].
In addition to genetic mechanisms, gene transcription
in eukaryotes is recently known to be subject to epige-
netic regulation that is independent of genomic DNA
sequences and is influenced l a r g e l yb ye n v i r o n m e n t a l
and developmental factors [9,10]. Chromatin remodel-
ing, DNA methylation and noncoding RNAs are three
known mechanisms of epigenetic regulation [10-12].
The major force in chromatin remodeling is the
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these modifications is the acetylation of the ε-amino
group of conserved lysine residues [14,15] that regulate
transcription and facilitate neuronal plasticity, thus
involving several neurological events [10,13,16-19]. His-
tone acetylation is catalyzed by histone acetyltransferase
and removed by histone deacetylases (HDACs) [14,20].
The mammalian genome contains at least 18 HDAC
genes that express proteins grouped into four classes:
class I (HDAC1, 2, 3, and 8), class II (HDAC4, 5, 7, 9 in
IIa, and HDAC6, 10 in IIb), class III (sirtuin1~7) and
class VI (HDAC11) [14,20,21]. These HDAC genes are
differentially expressed in the nervous system [22-24].
For example, the spinal cord expresses the genes of
HDAC1~8, and 11 [25-27]. Despite the finding that no
mRNA of the HDAC9 and 10 genes was detected by in
situ hybridization from the spinal cord [24], microarray
data deposited to the UCSC database http://www.ucsc.
edu and in situ hybridization data provided on-line by
Allen Institute http://www.brain-map.org showed the
presence of these mRNAs and those from all seven sir-
tuin genes in the spinal cord. However, the roles of dif-
ferent classes of HDACs in pain signal transmission in
the spinal cord have not been explored.
Animal studies demonstrated that the nociceptive
threshold increased in adult animals who experienced
stress in pre- and post-natal periods [28-31], during
which the nervous system is most sensitive to environ-
mental changes and subjected to epigenetic regulation
[32]. Human studies indicated that the genetic impact
on pain sensitivity in monozygotic twins diminished
with increasing age that apparently accompanies more
environmental exposures [33]. These observations sug-
gest that nociceptive sensitivity may be modified by
environmental and developmental factors in a way inde-
pendent of genetic mechanisms. To support this notion,
it was found that valproic acid (VPA) used as an antiepi-
leptic drug for prophylactic treatment of migraine
[34-37] and as an anticonvulsant to treat chronic cancer
pain [38] may broadly inhibit HDACs [39-42], although
VPA’se f f e c t so nG A B A e r g i ca c t i v i t y ,e x c i t a t o r yt r a n s -
mission and monoamines may affect nociception [43]. It
was also found that mice expressing partial loss-of-func-
tion of HDAC4 exhibited reduced thermal nociception,
but did not show a different response during the forma-
lin test in comparison to wild-type littermates [44]. In a
recent report, SAHA and MS-275 were used as HDAC
inhibitors (HDACIs) after a consecutive 5-day systemic
treatment and significantly reduced the second phase of
the formalin test in mice [27]. Another recent report
revealed that in a neuropathic pain model the neuron-
restrictive silencer factor exhibits long-lasting upregula-
tion in the dorsal root ganglion due to recruitment of
histone 4 to the second promoter of the gene.
Upregulated neuron-restrictive silencer factor may then
suppress expression of the μ-opioid receptor and Nav1.8
genes in C-fibers [45]. Taken together, these studies
suggest that epigenetic mechanisms may be involved in
modification of nociception and pathological pain. How-
ever, it remains largely unknown whether the nocicep-
tive pathway or which part of this pathway is involved.
In addition, except for a differential subcellular distribu-
tion among HDACs [23,46], the potential roles of each
class HDAC in the development of pathological pain are
still unknown.
In the present studies, we applied HDACIs, selective
to different classes of HDACs, to the spinal cord and
studied modification of the inflammatory thermal hyper-
algesia induced by CFA in mice. We observed that the
inhibition of class II HDACs is critical to attenuate
inflammatory hyperalgesia and the expression of the
members in class IIa HDACs in the spinal dorsal horn
was upregulated at the protein level following CFA
injection. In contrast, the inhibition of class I HDAC
with MS-275 showed no effect on CFA-induced thermal
hyperalgesia and in addition the expression of this class
of HDACs in the spinal cord was not induced by CFA.
Results
CFA-injected mice exhibited significant peak hypersensi-
tivity to a noxious heat stimulus at rest 30 min after the
injection (P < 0.01 compared to the baseline before the
injection, Fig. 1). This typical thermal hypersensitivity
appeared only on the hindpaw ipsilateral to the injection
side as reported [47]. The thermal hypersensitivity was
slowly resolved by 14 days after the injection. In con-
trast, the contralateral hindpaw showed no significant
changes compared to the baseline during the tested per-
iod (P > 0.05 compared to the baseline).
To explore the roles of HDACs in hyperalgesia, we
applied different HDACIs to the spinal cord via intrathe-
cal injection (i.t.). Considering that VPA was previously
reported to reduce tactile allodynia in a neuropathic pain
animal model after systemic administration [48] and is
widely used as an HDACI to suppress class I and IIa
HDACs [46,49], we first tested this inhibitor. As shown
in Fig. 2A, animals receiving vehicle injection exhibited
peak thermal hyperalgesia in response to CFA after
30 min as those without i.t. shown in Fig. 1. This CFA-
induced hypersensitivity was largely blocked in the early
time period after VPA preinje c t i o na n de v e ns h o w e dn o
significant difference from the baseline. This inhibition
exhibited dose dependency as shown in the inserted bar
graph at the one hour time point in Fig. 2A, and declined
5 hr after CFA injection, possibly due to the clearance of
the one-time injected inhibitor from tissues. However,
VPA is also known to interfere with GABAergic activity,
excitatory transmission and monoamines that are
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confirm whether HDAC activity is really involved in the
inhibition of hyperalgesia, we then tested three groups of
HDACIs specific to different classes of HDACs. These
inhibitors are SAHA, trichostatin A (TSA), and LAQ824
to target class I and II HDACs, 4-phenylbutyrate (4-PB)
to inhibit class I and IIa HDACs as well as MS-275 to
block class I HDACs only [19,46,50-54]. As shown in Fig.
2, CFA-induced thermal hyperalgesia was significantly
attenuated by all HDACIs, except for MS-275, in com-
parison to vehicle. No significant alteration of CFA-
induced effect was observed for MS-275, even though a
maximally soluble dose of 0.5 μgM S - 2 7 5i na5μl injec-
tion volume has been used. The attenuation lasted for a
short period of time approximately 3 hr or less after CFA
injection and showed dose dependency as indicated in
the inserted bar graphs for tested dose per injection of
1~25 μgf o rS A H A ,0 . 0 4 ~ 1μg for TSA, 8~200 ng for
LAQ824, and 10~250 μg for 4-PB. Of these tested HDA-
CIs, LAQ824 showed similar inhibitory effects between
40 and 200 ng suggesting saturation above 40 ng dosage.
In comparison, all other HDACIs showed increasing
effect following doses used. This observation prompted
us to evaluate the potential of each HDACI tested by
comparing their inhibitory effects on hyperalgesia at the
maximal doses 30 min after CFA (Fig. 2G). With the
exception of VPA, SAHA produced the strongest inhibi-
tion of hyperalgesia among tested inhibitors specific to
HDAC. In another group of studies, SAHA and VPA did
not interfere with thermal nociception in naïve mice
within the same tested time period as shown in Fig. 3.
We then questioned whether injected MS-275 under
the condition tested executed a similar pharmacological
effect as other HDACIs did. The direct targets of these
inhibitors are HDACs and the functional output of inhi-
bition of these enzymes can be assessed by the examina-
tion of the histone acetylation. Given the fact that all
HDACIs tested above retain the capability to pass the
blood-brain barrier [20,55-57], these inhibitors delivered
intrathecally may primarily target the spinal cord and
primary afferents. Therefore, we examined the effects of
i.t. SAHA and MS-275 on histone 3 (H3) acetylation in
the spinal cord in naïve mice. By immunoblot analysis,
H3 acetylation was measured relative to total (pan-) H3
protein by an antibody specific to acetylated H3 lysine 9
residue (H3K9ac) and one to pan-H3, respectively. As
shown in Fig. 4A and 4B, the relative H3K9ac signals in
animals injected either with SAHA or with MS-275
were largely enhanced in comparison to that in animals
receiving i.t. saline. Using an antibody specific to acety-
lated H3 lysine 9/18 (H3K9/18ac) for immunohisto-
chemistry, we further observed that 30 min after the
injection, the signals of H3K9/18ac robustly increased in
the lumbar spinal cord (Fig. 4C). It is of interest to note
that the superficial dorsal horn contained more H3K9/
18ac signals. As revealed by double-labeling with NeuN,
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Figure 1 Thermal hyperalgesia induced by CFA in mice. Paw withdrawal latency of mice to a thermal stimulus on hindpaws were measured
from both hind paws before and after unilateral CFA injection. Mean ± s.e. values from 10 animals were presented. Contl, contralateral side; Ipsi,
ipsilateral side.
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H3K9/18ac following SAHA or MS-275 treatments in
comparison to animals receiving vehicle. These results
indicate that histone acetylation in the lumbar spinal
cord has been enhanced by intrathecally injected HDA-
CIs and that MS-275 had a comparable effect on histone
acetylation as SAHA.
The mechanisms underlying the induction of persis-
tent pain may be different from those for its mainte-
nance. To test whether the spinal HDAC activity could
play a different role in these two events, we further stu-
died the effect of SAHA on existing thermal hyperalge-
sia. SAHA was intrathecally injected in mice that had
received intraplantar injection (i.pl.) of CFA for 1, 5 or
Figure 2 Short-term attenuation effects of pre-injected HDACI on thermal hyperalgesia in mice. Mice received intrathecally injected
vehicle or HDACI at indicated dose 30 min before unilateral injection of CFA. Paw withdrawal latency was measured before injections as
baseline, and after CFA injections as hyperalgesia response. Following HDACIs were injected for panel (in parenthesis) VPA (A), 4-BP (B), SAHA (C),
TSA (D), LAQ824 (E). The inserted bar graphs showed dose dependence from the time lined up with a dash line. Mean values of eight animals
per group plus standard errors are presented for the responses on the ipsilateral side. * P < 0.01, # P < 0.05: compared to vehicle at the same
time point. G. Comparison of inhibition of thermal hyperalgesia by tested HDACI. Inhibition of hyperalgesia by all inhibitors at the maximal dose
tested 30 min after CFA injection were calculated as described in method. One-way ANOVA analysis indicated there was no significant difference
among HDAC-specific inhibitors, but all of them showed significant difference in comparison to VPA (P < 0.05).
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hyperalgesia before i.t. (Fig. 5). This hypersensitivity was
significantly attenuated 30 min after i.t. SAHA in all
tested groups (P < 0.05) in comparison to the responses
of the same animals before i.t. or to the animals receiv-
ing i.t. vehicle.
Since studies above suggest that the activity of class II
HDACs in the spinal cord may be critical to induce or
maintain CFA-induced hyperalgesia, it is possible that
the expression of these enzymes is upregulated in
response to tissue damage to support persistent pain
hypersensitivity. To test this possibility, using immuno-
blot analysis, we quantitatively analyzed the levels of dif-
ferent HDACs (HDAC1, 2, 3 in class I and HDAC4, 5,
7, 9 in class IIa) in the lumbar dorsal spinal cord in ani-
mals at different time points after receiving CFA. First,
we observed for each tested HDAC the bands in the
sizes as suggested by manufacturers’ instructions. Then,
as shown by quantitative analysis in Fig. 6, the expres-
sion of members in class I HDACs was found to be
stable or be slightly reduced during the time period
examined, while those in class IIa HDACs were upregu-
lated significantly to different levels. Importantly, these
changes occurred in the early stage following CFA injec-
tion, but did not last longer than 24 hrs.
Discussion
Histone acetylation has been recognized as an important
mechanism in epigenetic regulation of gene transcrip-
tion [14,15]. One effective approach to test whether his-
tone acetylation impacts a biological event is to inhibit
HDAC and then assess the functional output of such an
inhibition. In this study, we found that pretreatment of
mice with HDACIs, including TSA, SAHA or LAQ824,
to target class I and II HDACs in the spinal cord signifi-
cantly produced a short-term attenuation of CFA-
induced thermal hyperalgesia in a dose-dependent man-
ner. A similar reduction was induced by HDACIs speci-
fic to class I and IIa HDACs (VPA and 4-PB) [46].
However, application of MS-275 to specifically inhibit
class I HDACs failed to attenuate the thermal hyperalge-
sia, even though it could increase H3 acetylation indicat-
ing inhibition of HDAC in the spinal cord (Fig. 4). Our
results suggest that a contribution of class I HDACs to
the thermal hyperalgesia induced by CFA can be
excluded. Then, the inhibited class II HDACs are likely
the major players in mediating the attenuation. In addi-
tion, analyses of expression of HDACs in the spinal
cord following tissue damage caused by CFA revealed
that the members in class IIa HDACs underwent upre-
gulation. Therefore, our data suggest that CFA-upregu-
lated class IIa HDACs in the spinal cord may facilitate
CFA-induced thermal hyperalgesia, and that the inhibi-
tion of class IIa HDACs may be sufficient to attenuate
the hyperalgesia.
In a recent report, the second phase of formalin-
induced inflammatory pain was reduced by systemically
injected MS-275 in the rat [27]. Specifically, MS-275
injected intraperitoneally at 3 mg/kg dosage produced
even more inhibition than SAHA at 5 mg/kg dosage. In
our studies, however, these two HDACIs i.t. at a similar
dose difference, i.e., 0.5 μg of MS-275 vs. 1 μg of SAHA,
exhibited significantly different effects on CFA-induced
thermal hyperalgesia (Fig. 2). This distinct effect of MS-
275 may be explained by following possibilities. First, in
our studies, intrathecal injection was used to deliver
HDACIs. This approach allows most injected drugs to
enter the spinal cord and indeed we observed that the
lumbar spinal HDACs were inhibited (Fig. 4). In con-
trast, systemic administration provides the opportunity
for all tissues to receive administered drug and thus to
Figure 3 Effects of HDACI on thermal nociception on naïve
mice. Naïve mice treated with i.t. SAHA (25 μg) or VPA (0.5 mg)
were tested for their hindpaw response to a noxious heat beam for
indicated time. Mean values + s.e. of PWL from 8 animals each
group were presented. No significance was revealed for comparison
among tested period either at the ipsilateral or contralateral side.
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These tissues include all structures in the nociceptive
pathway from the peripheral to the central nervous sys-
tem. Therefore, structures other than the spinal cord
may be targeted by systemically injected MS-275 and
involved in modulation of the pathological pain. Second,
the inflammatory pain induced by formalin differs from
that induced by CFA in aspects of duration and beha-
vioral changes [58-60], indicating different underlying
mechanisms. This notion is supported by a recent report
that animals bearing a partial loss-of-function of the
HDAC4 gene that belongs to class IIa HDACs exhibited
reduced thermal nociception, but no changes in forma-
lin response [44]. Third, in the present study, histone
acetylation was examined only for H3K9/18 and H3K9
following MS-275 or SAHA treatment. Changes in other
more than 18 lysine residues distributed among at least
four different subtypes of histones, i.e., histone 2A, 2B, 3
and 4, may occur [14,15], but were not examined.
Therefore, it is very likely that differential HDAC activ-
ities are involved in regulation of different models of
persistent pain or that different models of persistent
pain may be subjected to distinct epigenetic regulation.
In support of this functional difference among HDACs,
Figure 4 Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t.
SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens
indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown
in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.
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results in a hypersensitive response to chronic cocaine
reward or stress in mice [22].
Cell-type distribution of different HDAC isoforms is
another factor to be considered for the involvement of
specific class HDACs in processing pain signals. Histo-
chemically, distribution of most HDACs in the spinal
cord was viewed only by mRNA in situ hybridization
provided by the Allen Brain Atlas http://www.brain-
map.org/. Based on this database, neurons in the spinal
cord express almost all class I and II HDACs. Our data
also showed that most neurons (NeuN positive)
responded to HDACI treatment by exhibiting more sig-
nals of H3K9/18 and H3K9, while much fewer non-neu-
ronal cells showed increased H3 acetylation (Fig. 4C).
Taken together, these data suggest that HDAC in spinal
neurons may play a major role in persistent pain.
Acetylated histones are major substrates of HDACs
and thus modification of HDAC activity inevitably alters
gene expression via histone-involved chromatin remo-
deling. Therefore, gene regulation may be considered as
one molecular mechanism underlying the antihyperalge-
sic effect of HDACIs seen in this study. Genome-wide
analyses already revealed that increases in histone acety-
lation by HDACI even at rest alters mRNA levels of a
limited but still significant number of genes either by
upregulation or by downregulation [14]. For example,
infusion of MS-275 into the nucleus accumbens altered
expression of ~435 genes [61]. It is known that expres-
sion of a large number of genes in nociceptive pathways
impact normal nociception or persistent pain or both
[1-3]. Some of those genes may potentiate hypersensitiv-
ity while some of them may attenuate hyperactivity to
pain signals as evidenced by gene targeting studies in
animal models [1]. Some of these genes involved in
modification of nociceptive hypersensitivity may be sub-
jected to epigenetic regulation via histone acetylation
and thus mediate the antihyperalgesic effect of HDACIs.
For example, recently, the expression of the metabotro-
pic glutamate receptor 2 gene in the spinal cord and
dorsal root ganglion was found to be upregulated after
systemic administration of MS-275 or SAHA, and this
upregulation likely mediates the inhibitory effect of
these HDACIs on formalin-induced hyperalgesia [27].
Many other genes involved in persistent pain are also
regulated by HDACIs. For example, HDAC inhibition
increases the promoter activity of the opioid receptor
genes [62-64], whose products mediate the analgesic
effect of opioid peptides [65]. Another example is the
brain-derived neurotrophic factor gene that has been
deeply involved in the central sensitization [66,67], and
importantly whose promoters and transcription are
heavily regulated by histone acetylation [68-70]. Our
results in the present study indicate that inhibition of
class II HDACs attenuated thermal hyperalgesia, but not
the normal thermal nociceptive response in naïve ani-
mals which did not have spinal HDAC induction. On
the basis of all observations above, we expect that a
l a r g en u m b e ro fg e n e si nt h es p i n a lc o r du n d e r g o
expression alteration following HDACI treatment no
matter whether animals have been provoked by CFA or
not, and the net effect of such expression may favor an
attenuation of hypersensitivity to nociceptive stimuli,
but the maintenance of normal or unprovoked nocicep-
tion is not affected. We hypothesize that a pain-alleviat-
ing histone acetylation that is sensitive to class IIa
HDACs may reside in the spinal cord for the develop-
ment of persistent pain. The difference between the
gene expression profiles resulting from the inhibition of
class I HDACs and those following the inhibition of
class IIa HDACs is also of interest, in view of their dif-
ferent effect on thermal hyperalgesia. Illustration of this
difference in expression profile in the spinal cord may
eventually provide insight not only of functional differ-
ence of these HDACIs, but also the molecular mechan-
isms underlying HDACI’s antihyperalgesic activity. Our
observation that alteration of histone acetylation only
impacts persistent pain provides further evidence to
support the notion that persistent pain is regulated by
epigenetic mechanism [9].
In addition to histone, a few acetylated proteins can be
the substrates of HDACs, as well [14,15,46,71] and some
of these proteins may mediate the effects of HDCIs on
persistent pain via gene regulation or other mechanisms.
Recently, these proteins were searched globally and
found to include transcription factors, proteins partici-
pating in metabolism, cell cycle and signal transduction
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Figure 5 Attenuation of existing thermal hyperalgesia by
HDACI. Mice were treated with CFA i.pl. for indicated time and
then intrathecally injected with 25 μg SAHA for 30 min before
measurement of thermal response. Control animals were treated
with i.t. saline after CFA injection for the same time. Basal line was
measured before the CFA injection. Student t-test was used to
examine the significance as indicated groups. * P < 0.01.
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involves a pathway regulating inflammatory pain hyper-
sensitivity [7,75,76]. In view of the short duration of the
HDACI effect, it is possible that acetylation in proteins
other than histones was accumulated under the pressure
of HDACIs, thus inducing the attenuation of hyperalge-
sia. This possibility is also supported by three facts.
First, class IIa HDAC members are actively exported
from the nucleus [14,15,77], which provides the oppor-
tunity for these enzymes to act on non-nuclear proteins
that have been acetylated. Second, class IIa HDACs
showed very low activity on acetylated histone used in
in vitro test and were proposed to efficiently act on a
narrow set of undiscovered substrates [78]. Third, class
IIa HDACs interact with different non-histone proteins
from those that are associated with class I or class IIb
HDACs [14,79], even in face of our poor understanding
of the selectivity of HDACs on acetylated lysines in his-
tone subtypes [13].
Conclusions
The present study demonstrates that inhibition of
HDAC in the spinal cord results in a short-term
attenuation of thermal hyperalgesia induced by the
Figure 6 Changes of HDACs’ levels in the dorsal spinal cord after CFA injection into the hindpaw. The levels of HDACs in the dorsal
spinal cord were analyzed by immunoblot using antibodies specific to each target as indicated. Examples of blots are shown in A and C.
Digitally analyzed levels of each HDAC after normalization to b-actin are shown in B for class I HDACs and in D for class IIa HDACs. Mean values
plus s.e. are averaged from 4 to 6 animals. Student t-test was used to examine the significance as indicated groups. * P < 0.01; ** P < 0.05.
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a major role in this antihyperalgesic effect. This class of
HDAC also exhibits upregulation in response to CFA,
suggesting that the member si nc l a s sI I aH D A C sa r e
potential targets for attenuation of persistent inflamma-
tory pain. These data indicate that epigenetic regulation
in the spinal cord participates in the development of
persistent pain and analgesic effects resulting from inhi-
bition of selective HDACs provides a novel target for
the development of analgesic drugs.
Methods
Animal and behavior studies. Mice (male, C57BL/
6NTac, 6-7 weeks, ~20-22gr, Taconic Farm) were pur-
chased from Taconic. All animals received care in com-
p l i a n c ew i t ht h eG u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals (NIH pub No. 86-23). All experi-
ments involving animals were conducted according to
the protocol approved by the Institutional Animal Care
and Use Committee at University of Maryland. Intrathe-
cal injection was performed as reported previously [80]
with a 5 μlv o l u m et ob ec o m p l e t e di n5m i n .H D A C I s
were obtained from the following sources (in parenth-
esis): VPA (Axxora Life Sciences), 4-PB (Enzo Biochem),
TSA (Cell Signaling Technologies), SAHA (Cayman
Chemical), MS-275 and LAQ824 (Selleck). Saline or 1%
DMSO served as vehicle. Control animals received vehi-
cle injection. After the intraplantar injection (i.pl.) of 10
μl of CFA (Sigma, diluted 1:4 with saline) to the left
hindpaw, the time of paw withdrawal latency (PWL) to
noxious heat was measured from both hindpaws using a
system described previously [81]. The injected hindpaw
showed edema and erythema indicating inflammation
[81]. Intrathecal injection was completed either 30 min
before CFA injection or at the selected time after CFA
injection. Each experimental group included 8 to 10 ani-
mals. All experiments were performed blind for injec-
tion and behavioral test. Reversed hyperalgesia was
calculated as follows. The PWL differences between the
baseline and the treatment of i.t. vehicle followed by i.
pl. CFA for a selected time were regarded as the 100%
hypersensitivity. The PWL differences between the base-
line and the treatment of i.t. tested HDACI followed by
i.pl. CFA for the same selected time were regarded the
modified hypersensitivity. The differences between the
100% and modified hypersensitivity are the inhibitory
effect of tested HDACI.
The effect of intrathecal injection on the spinal target
was examined by analyzing histone acetylation 30 min
after i.t. selected HDACI by immunohistochemistry and
immunoblot using three fresh mice per HDACI per
technology. For HDAC expression studies, CFA or sal-
ine was injected bilaterally to naïve mice as described
above for the time points indicated in Fig. 6. Four to six
mice were used for each time point per treatment (CFA
or saline) or for naïve animals.
Immunoblot analysis. Immunoblot analysis was carried
out as described previously [82]. Naïve or treated ani-
mals were sacrificed at selected time points. Spinal
cords were quickly pushed out by injecting saline into
the spine. The dorsal half of the lumbar spinal cord
equal to the L4 to L5 segments were quickly dissected
out, frozen on dry ice and saved at -80°C until use. To
test the effect of HDACI, the whole lumber spinal cord
was collected. Tissue lysates were prepared by homoge-
nizing dissected spinal cord in RIPA buffer plus protease
inhibitor cocktail (Roche) in a Teflon-glass tissue grin-
der followed by 10 min centrifugation at 15,000xg.
Lysates (16 μg protein/lane) were fractionated on 7 or
10% polyacrylamide-SDS gel in a glycine-Tris buffer and
transferred to a PVDF membrane. Primary antibodies
were obtained from Cell Signaling Technology for
HDAC1, 2, 3, 4, 5, 7 and Santa Cruz Biotechnology for
HDAC9, and were diluted by 1:1,000 in PBST. Histone
was examined by an antibody specific to acetylated his-
tone 3 Lys9 (H3K9ac, Upstate/Millipore) and by an anti-
body specific to pan-H3 (Upstate/Millipore). Enhanced
chemical luminescence was used to reveal and quantify
signals associated with the specific antigen to be
detected. Signals associated with the specific immune
complex were analyzed and normalized to b-actin as
described previously [82].
Immunohistochemistry. Immunostaining of spinal
cord was conducted as described previously [83]. Briefly,
mice were perfused with 5% paraformaldehyde/PBS after
selected treatments. Spinal cord was dissected out and
subjected to post-fixation 5% with paraformaldehyde/
PBS and cryostat protection in 30% sucrose/PBS. Trans-
verse sections in 30 μm thick were made of the lumbar
section of the spinal cord in a cryostat and mounted
directly onto glass slides (Fisher Scientific). Immunos-
taining was performed on the glass slides with a rabbit
antibody against acetylated histone 3 (H3K9/18ac,
Upstate/Millipore) and a mouse monoclonal antibody
against NeuN (Chemicon/Millipore). Primary antibodies
were visualized by anti-rabbit IgG antibody conjugated
with Cy3 and anti-mouse IgG antibody labeled with Cy2
(Jackson ImmunoResearch laboratories), respectively.
Data processing: One way ANOVA with post hoc
Tukey’s test was used for statistical analysis of the data
among multiple groups. All data presented in figures are
mean values of indicated animals plus standard error.
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